In this interview:
- Ipilimumab in metastatic or locally advanced, unresectable melanoma (Hodi F)
- Analysis of relationship between PFS and OS (Flaherty KT)
- The BRIM7 study: results on the combination of BRAF inhibitor, Vemurafenib and MEK inhibitor, Cobinetinib (McArthur G)
For more information:
Abstracts: Melanoma and Skin Cancer
- Abstract: # 24. Author and Title: Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Chen TT, Berman DM, Wolchok JD. LATE BREAKING ABSTRACT: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. [Abstract Link]
- Abstract: # 3702. Author and abstract: Flaherty KT, Lee SJ, Dummer R, Hauschild A, Hennig M, Long GV, Lorigan P, Robert C, Schadendorf D. A meta-analysis of randomized, controlled trials in metastatic melanoma establishes progression-free survival as a surrogate for overall survival. [Abstract Link]
- Abstract: # 3703. Author and abstract: McArthur G, Gonzalez R, Pavlick A, Hamid O, Puzanov I, Gajewski TF, Daud A, Yin M, Choong N, Ribas(9)
Vemurafenib (VEM) and MEK inhibitor, cobimetinib (GDC-0973), in advanced BRAFV600-mutated melanoma (BRIM7): dose-escalation and expansion results of a phase IB study. [Abstract Link]
This interview is produced in collaboration with
 |  |
Copyright ? 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
